Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The predictive role of contrast-enhanced ultrasonography (CEUS) before performing transarterial chemoembolization (TACE) has not been determined. We assessed the possible predictive factors of CEUS for the response to TACE. Methods: Seventeen patients with 18 hepatocellular carcinoma (HCC) underwent TACE. All of the tumors were studied with CEUS before TACE using a second-generation ultrasound contrast agent (SonoVue®, Bracco, Milan, Italy). The tumor response to TACE was classified with a score between 1 and 4 according to the remaining enhancing-tumor percentage based on modified response evaluation criteria in solid tumors (mRECIST): 1, enhancing tumor <25%; 2, 25%≤enhancing tumor<50%; 3, 50%≤enhancing tumor<75%; and 4, enhancing tumor≥75%). A score of 1 was defined as a “good response” to TACE. The predictive factors for the response to TACE were evaluated during CEUS based on the maximum tumor diameter, initial arterial enhancing time, arterial enhancing duration, intensity of arterial enhancement, presence of a hypoenhanced pattern, and the feeding artery to the tumor. Results: The median tumor size was 3.1 cm. The distribution of tumor response scores after TACE in all tumors was as follows: 1, n=11; 2, n=4; 3, n=2; and 4, n=1. Fifteen tumors showed feeding arteries. The presence of a feeding artery and the tumor size (≤5 cm) were the predictive factors for a good response (P=0.043 and P=0.047, respectively). Conclusions: The presence of a feeding artery and a tumor size of less than 5 cm were the predictive factors for a good response of HCC to TACE on CEUS. (Clin Mol Hepatol 2015;21:158-164)
Abstract
Background/Aims: The predictive role of contrast-enhanced ultrasonography (CEUS) before performing transarterial chemoembolization (TACE) has not been determined. We assessed the possible predictive factors of CEUS for the response to TACE. Methods: Seventeen patients with 18 hepatocellular carcinoma (HCC) underwent TACE. All of the tumors were studied with CEUS before TACE using a second-generation ultrasound contrast agent (SonoVue®, Bracco, Milan, Italy). The tumor response to TACE was classified with a score between 1 and 4 according to the remaining enhancing-tumor percentage based on modified response evaluation criteria in solid tumors (mRECIST): 1, enhancing tumor <25%; 2, 25%≤enhancing tumor<50%; 3, 50%≤enhancing tumor<75%; and 4, enhancing tumor≥75%). A score of 1 was defined as a “good response” to TACE. The predictive factors for the response to TACE were evaluated during CEUS based on the maximum tumor diameter, initial arterial enhancing time, arterial enhancing duration, intensity of arterial enhancement, presence of a hypoenhanced pattern, and the feeding artery to the tumor. Results: The median tumor size was 3.1 cm. The distribution of tumor response scores after TACE in all tumors was as follows: 1, n=11; 2, n=4; 3, n=2; and 4, n=1. Fifteen tumors showed feeding arteries. The presence of a feeding artery and the tumor size (≤5 cm) were the predictive factors for a good response (P=0.043 and P=0.047, respectively). Conclusions: The presence of a feeding artery and a tumor size of less than 5 cm were the predictive factors for a good response of HCC to TACE on CEUS. (Clin Mol Hepatol 2015;21:158-164)
참고문헌 (28)
- Forner A, "Hepatocellular carcinoma", Lancet, 379, pp.1245~1255 (2012)
- Tsochatzis EA, "Liver cirrhosis", Lancet, 383, pp.1749~1761 (2014)
- Lencioni R, "Chemoembolization for hepatocellular carcinoma", Semin Oncol, 39, pp.503~509 (2012)
- Tsochatzis EA, "Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment", Semin Oncol, 37, pp.89~93 (2010)
- Fatourou EM, "Adaptive immunity in hepatocellular carcinoma : prognostic and therapeutic implications", Expert Rev Anticancer Ther, 9, pp.1499~1510 (2009)
- Tsochatzis EA, "Transarterial chemoemboliza-tion and bland embolization for hepatocellular carcinoma", World J Gastroenterol, 20, pp.3069~3077 (2014)
- Tsochatzis EA, "Transarterial therapies for hepato-cellular carcinoma", Recent Results Cancer Res, 190, pp.195~206 (2013)
- Matsui O, "Small hepatocellular carcinoma : treatment with subsegmental transcatheter arterial embolization", Radiology, 188, pp.79~83 (1993)
- Iwamoto S, "Angiographic subsegmentectomy for the treatment of patients with small hepatocellular carcinoma", Cancer, 97, pp.1051~1056 (2003)
- Schneider M, "Characteristics of SonoVuetrade mark", Echocardiography, 16, pp.743~746 (1999)
- Nicolau C, "Importance of evaluating all vascular phases on contrast-enhanced sonography in the differentiation of benign from malignant focal liver lesions", AJR Am J Roentgenol, 186, pp.158~167 (2006)
- Trillaud H, "Characterization of focal liver lesions with SonoVue-enhanced sonography : international multicenter-study in comparison to CT and MRI", World J Gastroenterol, 15, pp.3748~3756 (2009)
- Lee JM, "2014 KLCSG-NCC Korea Practice Guidelines for the management of hepatocellular carcinoma : HCC diagnostic algorithm", Dig Dis, 32, pp.764~777 (2014)
- Ueno S, "Prognostic per-formance of the new classification of primary liver cancer of Japan(4th edition)for patients with hepatocellular carcinoma : a validation analysis", Hepatol Res, 24, pp.395~403 (2002)
- Lencioni R, "Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy", Crit Rev Oncol Hematol, 83, pp.216~224 (2012)
- Lencioni R, "Local-regional treatment of hepatocellular carcinoma", Radiology, 262, pp.43~58 (2012)
- Adler L, "Determination of the Nonlinearity Parameter B", A for Water and m‐Xylene, 1962, pp.34, 410~412
- Thomas JD, "Tissue harmonic imaging: why does it work?", J Am Soc Echocardiogr, 11, pp.803~808 (1998)
- Piscaglia F, "Characterization of focal liver lesions with contrast-enhanced ultrasound", Ultrasound Med Biol, 36, pp.531~550 (2010)
- Harvey CJ, "Pulse-inversion mode imaging of liver specific microbubbles : improved detection of subcentimetre metastases", Lancet, 355, pp.807~808 (2000)
- Bolondi L, "New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice", Dig Liver Dis, 39, pp.187~195 (2007)
- Lencioni R, "Tissue harmonic and contrastspecific imaging : back to gray scale in ultrasound", Eur Radiol, 12, pp.151~165 (2002)
- Jang JY, "Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions", Clin Mol Hepatol, 19, pp.1~16 (2013)
- Wilson SR, "Enhancement patterns of focal liver masses: discord-ance between contrast-enhanced sonography and contrast-enhanced CT and MRI", AJR Am J Roentgenol, 189, pp.W7~W12 (2007)
- Lencioni R, "Contrast-enhanced ultrasound in the diagnosis of hepatocel-lular carcinoma", J Hepatol, 48, pp.848~857 (2008)
- Strobel D, "Contrast-enhanced ultrasound for the characterization of focal liver lesions--diagnostic accuracy in clinical practice(DEGUM multicenter trial)", Ultraschall Med, 29, pp.499~505 (2008)
- Kwan SW, "Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma : a radiological-pathological correlation", Liver Transpl, 18, pp.727~736 (2012)
- Moschouris H, "Contrast-enhanced ultrasonography with intraarterial administration of SonoVue for guidance of transarterial chemoembolization : an initial experience", Med Ultrason, 13, pp.296~301 (2011)